123 related articles for article (PubMed ID: 38176404)
1. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.
Hagen P; Norton J; Tsai S; Campo L; Lee M; Gomez K; Stiff P
Br J Haematol; 2024 Apr; 204(4):1422-1428. PubMed ID: 38176404
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
3. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Visram A; Hayman SR; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Warsame R; Kourelis T; Cook J; Binder M; Gonsalves W; Muchtar E; Leung N; Roy V; Rajkumar SV; Kumar S
Am J Hematol; 2023 Aug; 98(8):1277-1285. PubMed ID: 37334773
[TBL] [Abstract][Full Text] [Related]
7. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
[TBL] [Abstract][Full Text] [Related]
8. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
9. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Nieto Y; Yang Z; Valdez BC; Kundu S; Bashir Q; Ramdial J; Srour S; Qazilbash M
Am J Hematol; 2024 Feb; 99(2):245-253. PubMed ID: 38100199
[TBL] [Abstract][Full Text] [Related]
12. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R
Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145
[TBL] [Abstract][Full Text] [Related]
13. Busulfan plus melphalan
Park S; Shin DY; Hong J; Kim I; Koh Y; Byun JM; Yoon SS
Ther Adv Hematol; 2021; 12():20406207211012985. PubMed ID: 33995990
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m
Gao F; Lin MS; You JS; Zhang MY; Cheng L; Lin K; Zhao P; Chen QY
Cancer Cell Int; 2021 Nov; 21(1):601. PubMed ID: 34758834
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Leleu X; Fouquet G; Richez V; Guidez S; Duhamel A; Machuron F; Karlin L; Kolb B; Tiab M; Araujo C; Meuleman N; Malfuson JV; Bourquard P; Lenain P; Roussel M; Jaccard A; Pétillon MO; Belhadj-Merzoug K; Lepeu G; Chrétien ML; Fontan J; Rodon P; Schmitt A; Offner F; Voillat L; Cereja S; Kuhnowski F; Rigaudeau S; Decaux O; Humbrecht-Kraut C; Frayfer J; Fitoussi O; Roos-Weil D; Eisenmann JC; Dorvaux V; Voog EG; Attal M; Moreau P; Avet-Loiseau H; Hulin C; Facon T
Clin Cancer Res; 2019 Jul; 25(14):4224-4230. PubMed ID: 31053600
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
[TBL] [Abstract][Full Text] [Related]
17. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.
Byun JM; Lee J; Shin SJ; Kang M; Yoon SS; Koh Y
Blood Res; 2018 Jun; 53(2):105-109. PubMed ID: 29963515
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
20. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
Hagen P; D'Souza A; Hari P; Davila O; Zhang MJ; Vesole DH; Smith SE; Rodriguez TE; Stiff PJ
Leuk Lymphoma; 2020 Dec; 61(14):3484-3492. PubMed ID: 32865474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
